Skip to main content
H

HEXIMA LIMITED. — Investor Relations & Filings

Ticker · HXL ISIN · AU0000111932 ASX Professional, scientific and technical activities
Filings indexed 244 across all filing types
Latest filing 2022-09-29 Regulatory Filings
Country AU Australia
Listing ASX HXL

About HEXIMA LIMITED.

https://hexima.com.au/

Hexima Limited focuses on the research and development of plant-derived proteins for human therapeutic applications. The company's primary development candidate is pezadeftide (HXM163), a proprietary plant defensin formulated as a topical treatment for onychomycosis, a fungal nail infection. Pezadeftide is engineered to penetrate the nail plate and target underlying fungal pathogens. The company's technology platform utilizes the natural defense mechanisms of plants to develop novel antimicrobial and antifungal treatments. Originally focused on agricultural biotechnology, the company transitioned to human health to address unmet needs in dermatology. Its activities involve the clinical evaluation of protein-based therapies designed to offer improved efficacy and safety profiles compared to existing antifungal treatments.

Recent filings

Filing Released Lang Actions
Annual Report 2022 73 pages 1.3MB
Regulatory Filings
2022-09-29 English
Appendix 4G and Corporate Governance Statement 29 pages 680.6KB
Regulatory Filings
2022-09-29 English
2022 Annual General Meeting Date 1 page 145.6KB
Regulatory Filings
2022-09-29 English
Change in substantial holding 2 pages 238.7KB
Regulatory Filings
2022-09-26 English
Change of Address 1 page 103.8KB
Regulatory Filings
2022-09-11 English
Becoming a substantial holder 2 pages 195.8KB
Regulatory Filings
2022-09-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.